Qiagen N.V. $QGEN Stake Raised by Farther Finance Advisors LLC

Farther Finance Advisors LLC increased its holdings in Qiagen N.V. (NYSE:QGEN) by 400.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,061 shares of the company’s stock after buying an additional 849 shares during the quarter. Farther Finance Advisors LLC’s holdings in Qiagen were worth $51,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in Qiagen by 12.2% during the 1st quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company’s stock worth $972,191,000 after acquiring an additional 2,656,136 shares during the period. Deutsche Bank AG raised its stake in shares of Qiagen by 57.5% during the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company’s stock valued at $180,319,000 after purchasing an additional 1,639,621 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Qiagen by 3,030.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company’s stock valued at $179,501,000 after purchasing an additional 4,327,934 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Qiagen by 4.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company’s stock worth $96,605,000 after purchasing an additional 109,481 shares during the period. Finally, Caisse Des Depots ET Consignations lifted its holdings in Qiagen by 7.3% in the first quarter. Caisse Des Depots ET Consignations now owns 1,345,657 shares of the company’s stock worth $53,374,000 after purchasing an additional 91,357 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of NYSE QGEN opened at $46.99 on Tuesday. The stock’s fifty day simple moving average is $47.35 and its 200 day simple moving average is $45.37. The stock has a market capitalization of $10.45 billion, a price-to-earnings ratio of 27.76, a PEG ratio of 2.47 and a beta of 0.66. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million for the quarter, compared to analysts’ expectations of $523.97 million. During the same quarter last year, the business posted $0.55 EPS. Qiagen’s revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, sell-side analysts forecast that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Friday. Bank of America increased their price objective on shares of Qiagen from $50.00 to $53.00 and gave the company a “buy” rating in a report on Thursday, June 26th. Barclays set a $53.00 target price on Qiagen and gave the stock an “overweight” rating in a report on Thursday. Weiss Ratings restated a “hold (c+)” rating on shares of Qiagen in a research report on Saturday, September 27th. Finally, Cowen reiterated a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $49.40.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.